Trial
NCT03334812
Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Knee Cartilage Lesion
Intervention
LNA043
Why stopped
This study was terminated early based on an interim analysis of 14 subjects, which demonstrated a favorable safety and tolerability profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-07